advertisement
Li W 17
Showing records 1 to 17 | Display all abstracts from Li W104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Sun X
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Xiong K
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Liu Q
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Wang L; Li W
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Tang X
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Wang W
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yao K
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Meng J
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li Y
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Gong X
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yang J; Zhang M
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Lu P
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yuan H
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Liang X; Huang J
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Zheng Y
BMC Ophthalmology 2022; 22: 332
105034 Risk of acute angle-closure and changes in intraocular pressure after pupillary dilation in patients with diabetes
Huang W
Eye 2023; 37: 1646-1651
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li W; Peng H
BMC Ophthalmology 2022; 22: 332
